Fu Lei, Wang Rong, Yin Ling, Shang Xiaopu, Zhang Runtong, Zhang Pengjun
Core Laboratory of Translational Medicine, Chinese PLA General Hospital, Beijing, China.
Joint Logistics College, National Defence University of PLA, Beijing, China.
Genet Mol Biol. 2020 Feb 14;42(4):e20180234. doi: 10.1590/1678-4685-GMB-2018-0234. eCollection 2020.
We aimed to analyze the correlation between ABCG2 gene polymorphisms of 34 GG/(GA + AA) loci, 421 CC/(AC + AA) loci, and non-small cell lung cancer (NSCLC) therapeutic effects via meta-analysis. With key words, the databases PubMed and EMBASE were searched for clinical studies on ABCG2 polymorphism and NSCLC. RR and 95% CIs were used to compute combined effects, followed by heterogeneity testing. Publication bias was examined using the funnel plot method. Review Manager 5.3 software was used for the meta-analysis. Ten studies were included. No evidence of heterogeneity exists in these studies. The results indicate that two polymorphic loci of ABCG2 gene (34 G>A, and 421 C>A) had no relationship with the curative effect of chemotherapy for NSCLC, except ABCG2 34G>A, which had a significant relationship with the skin toxicity complication. There was no significant relationship between these polymorphisms and complications (skin toxicity, diarrhea, interstitial pneumonia, liver dysfunction, and neutropenia). Begg's test and Egger's test indicated that there was no obvious publication bias. The meta-analysis indicated that there was no significant correlation between ABCG2 gene polymorphism and NSCLC outcomes.
我们旨在通过荟萃分析，分析34个GG/（GA + AA）位点、421个CC/（AC + AA）位点的ABCG2基因多态性与非小细胞肺癌（NSCLC）治疗效果之间的相关性。通过关键词检索PubMed和EMBASE数据库，查找关于ABCG2基因多态性与NSCLC的临床研究。采用RR和95%可信区间计算合并效应，随后进行异质性检验。使用漏斗图法检验发表偏倚。采用Review Manager 5.3软件进行荟萃分析。纳入10项研究。这些研究中不存在异质性证据。结果表明，ABCG2基因的两个多态性位点（34 G>A和421 C>A）与NSCLC化疗疗效无关，但ABCG2 34G>A与皮肤毒性并发症有显著关系。这些多态性与并发症（皮肤毒性、腹泻、间质性肺炎、肝功能障碍和中性粒细胞减少）之间无显著关系。Begg检验和Egger检验表明不存在明显的发表偏倚。荟萃分析表明，ABCG2基因多态性与NSCLC预后无显著相关性。
